A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
To demonstrate statistical superiority of the combination of latanoprost and timolol to the
individual therapy of latanoprost and timolol based on intraocular pressure measurements at 8
AM, 10 AM, 4 PM at weeks 2, 6 and 12.
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.